Myth-buster
Platelet count trajectory predicted sepsis mortality (HR 0.97 per 10^9/L rise), but vitamin C had no effect on that link — null result from 863-patient trial.
This post-hoc analysis of the LOVIT trial contradicts the hope that high-dose vitamin C could reduce sepsis mortality through platelet effects, and adds to a body of evidence (1 beneficial, 4 neutral) showing no clear benefit.
Researchers analyzed data from 863 sepsis patients to see if vitamin C's lack of effect on mortality might be explained by platelet count changes. While rising platelet levels over four days were linked to lower death risk (28% lower per 10 billion/L increase), vitamin C did not alter that trajectory or improve survival. This null result, from a post-hoc analysis of a trial that already found no overall benefit, reinforces that vitamin C does not reduce mortality in sepsis — despite its anti-inflammatory reputation.
Where this fits in the evidence
Pillser has synthesized 7 studies on Vitamin C for Reduced Mortality Risk — overall evidence strength: Low.
Across 7 studies on vitamin C and mortality risk, the evidence is predominantly neutral with 5 studies reporting small null effects, 1 beneficial meta-analysis showing a moderate reduction in mortality risk (OR=0.64, 95% CI 0.51-0.80), and 1 harmful review citing harm from high-dose vitamin C in sepsis and COVID-19. The most-studied populations are clinical patients with sepsis, septic shock, or COVID-19. Median study duration was 4 days among the one study that reported duration, limiting insight into long-term effects.
The study
- Randomized Controlled Trial (RCT)
- n = 863
- 2025-09
- Critical care explorations
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.